🚨The latest National Prostate Cancer Audit Newsletter is OUT, you can read it here www.natcan.org.uk/news/npca-ne...

Packed full of news, information and links! Please share it widely.

@natcan-news.bsky.social @hqip.bsky.social

A higher rate of metastatic prostate cancer and a lower rate of prostate cancer overall was also seen among men living in more deprived neighbourhoods, suggesting that the risk of being diagnosed with metastatic prostate cancer is also linked to their socioeconomic background.

⚠️ Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing.

🚨 Regional annual rates were found to vary between 4 and 7 per 100 000 men, with the highest rates seen in Northern England; South Yorkshire and Bassetlaw; Humber, Coast and Vale; West Yorkshire and Harrogate; and the Peninsula. The lowest rates were seen in London and the South-East.

Everything you ever wanted to know about the National Cancer Audit Collaboration Centre (NATCAN @natcan-news.bsky.social), which the prostate audit is part of, is now available in a very handy summary paper form!

Read it here www.sciencedirect.com/science/arti...

Please share it far and wide!

The study explored variation in treatment intensification for mHSPC across England and found

👉 Only 39% received intensification with lower uptake in Black and deprived populations

👉 Intensification was given to 60% of men under 75 but dropped to 17% in those over 75

🚨 Our March 2025 Newsletter is out! www.npca.org.uk/news/npca-ma...

Summarising our findings from the State of the Nation Report www.npca.org.uk/reports/npca... and linking to our latest quarterly report www.npca.org.uk/reports/npca...

Read it and share!

Do you want to help strengthen NHS cancer services & reduce variation in prostate cancer care? Are you a clinical oncological or urological trainee looking to pursue an MD or PhD with an expert clinical/audit team at the National Cancer Audit Collaborating Centre (NATCAN) buff.ly/4hW4zHz?

We also present the annual percentage of men with low-risk cancer (CPG1) who received radical treatment by age in England from 1st January 2021 to 31st December 2023.

We present the annual percentage of men with high-risk/locally advanced prostate cancer who received treatment by ethnicity and by IMD fifth separately in England from 1st January 2021 to 31st December 2023.

We report the annual number of new diagnoses per 1000 male population by stage, age and IMD fifth in white men, in England from 1st January 2021 to 31st December 2023.

We report the annual number of new diagnoses per 1000 male population aged 65 to 84 years with a recorded stage at diagnosis, by stage and ethnicity, in England from 1st January 2021 to 31st December 2023.

We also present a relative count per 1000 men in the population of new prostate cancer diagnoses by age, ethnicity and Index of Multiple Deprivation fifth, in England from 1st January 2021 to 31st December 2023.

In this report, we present the count of new prostate cancer diagnoses by age, ethnicity and Index of Multiple Deprivation (IMD) fifth, in England from 1st January 2021 to 31st December 2023. Data for Wales were not available for this section.

The results for our six performance indicators remained stable in both England and Wales when comparing with the previous reporting period (which differs by nation and indicator). All our previous reports are available here www.npca.org.uk/reports

Key findings include an increase in men newly diagnosed with prostate cancer: in 2023 in England, a 9% increase when compared to 2022 and a 25% increase compared to 2019. In 2022 in Wales, a 26% increase compared to 2021.